ClinicalTrials.Veeva

Menu
H

Henderson Clinical Trials | Henderson, NV

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TAK-279
Lorundrostat
Amlitelimab
AD109
Aroxybutynin
XYWAV
Retatrutide
PF-07817883
Atomoxetine
High-Sodium Oxybate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 15 total trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling
Seasonal Influenza
Biological: Fluarix®
Biological: Influsplit®
Locations recently updated

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody re...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Biological: Tdap vaccine

The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned...

Active, not recruiting
Narcolepsy
Drug: JZP258

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment.The purpo...

Active, not recruiting
Asthma
Drug: Placebo
Drug: Amlitelimab

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the air...

Enrolling
Asthma
Drug: dupilumab
Drug: Matching Placebo

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypert...

Invitation-only
Hypertension
Drug: lorundrostat
Drug: Placebo

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: AD109
Drug: Placebo

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with mediu...

Begins enrollment this month
Eosinophilic Asthma
Combination Product: Placebo for Benralizumab
Combination Product: benralizumab

The goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive...

Enrolling
Obstructive Sleep Apnea
Drug: Acetazolamide
Drug: IHL-42X Low Dose

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Apnimed logo
M
Sanofi logo
Takeda logo
AstraZeneca logo
I
Jazz Pharmaceuticals logo
Lilly logo
Moderna logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems